Effect of Cilostazol on Myocardial Histomorphological Changes in Ischemia-Reperfusion Injury

Anar Amrah 1 * , Fazil Abbasov 2, Mamed Karimov 3, Ziya Shahaliyev 1, Artan Jahollari 4, Murat Tavlashoglu 4, Mustafa Kurkluoglu 4
More Detail
1 Department of Cardiovascular Surgery, Republican Diagnostics Center, Baku, Azerbaijan
2 Department of Cardiovascular Surgery, Educational Scientific Center named after Topchubasov, Baku, Azerbaijan
3 Department of Cardiovascular Surgery, I. M. Sechenov First State Moscow Medical University Baku branch, Baku, Azerbaijan
4 Department of Cardiovascular Surgery, Gulhane Military Medical Academy, Ankara, Turkiye
* Corresponding Author
J CLIN MED KAZ, Volume 22, Issue 2, pp. 19-23. https://doi.org/10.23950/jcmk/16189
OPEN ACCESS 262 Views 93 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, A. A. and Z. S.; methodology, A. A., F. A., and Z. S.; validation, A. A., F. A., M. K., and Z. S.; formal analysis, F. A., M. K., and Z. S. ; investigation, A. A., A. J., M. T., and M. K.; resources, A. A., F. A., M. K., and Z. S.; data curation, A. A., F. A., and Z. S.; writing – original draft preparation, F. A., and Z. S.; writing – review and editing, A. A., F. A., and Z. S.; visualization, A. A., and Z. S.; supervision, A. A., and F. A.; project administration, A. A., F. A., and Z. S.; funding acquisition, A. A. All authors have read and agreed to the published version of the manuscript.

ABSTRACT

Introduction: Protecting the myocardium from acute ischemia-reperfusion (IR) injuries during open-heart surgeries is vital for improving outcomes. This study aimed to compare the effects of cilostazol on the nature and extent of histomorphological changes in the myocardium in a rat IR injury model.
Material and Methods: Wistar Albino rats were divided into three groups of eight. The Sham group underwent no coronary occlusion. In the IR group, the left anterior descending artery(LAD) was compressed for 45 minutes to induce acute ischemia, followed by 180 minutes of reperfusion. In the cilostazol group, 20 mg/kg/day cilostazol was administered orally for two weeks before IR induction. Rats were euthanized, and 3 mm myocardial slices were prepared for histomorphological analysis. Changes were assessed at four levels, and total, damaged, and necrotic areas were measured planimetrically. Comparisons were made using Student’s t-test, with P<0.05 considered significant.
Results: Pathohistological changes in the IR and cilostazol groups were classified as “mild” in 37.5%/53.1% (P=0.008) and “moderate” in 50.0%/43.8% (P<0.05) respectively. “Severe” changes occurred in 12.5% of IR and 3.1% of cilostazol cases (P=0.006). Ischemic and necrotic areas in the IR group (10.60±1.33 mm² and 5.76±0.62 mm²) were significantly reduced in the cilostazol group (6.94±0.73 mm² and 4.04±0.58 mm², P<<0.01).
Conclusion: Cilostazol at 20 mg/kg/day for two weeks before IR injury significantly reduced myocardial ischemic and necrotic areas, showed positive results in histopathological examination demonstrating a strong cardioprotective effect.
Keywords: cilostazol, ischaemia-reperfusion injury, cardiac surgery

CITATION

Amrah A, Abbasov F, Karimov M, Shahaliyev Z, Jahollari A, Tavlashoglu M, et al. Effect of Cilostazol on Myocardial Histomorphological Changes in Ischemia-Reperfusion Injury. J CLIN MED KAZ. 2025;22(2):19-23. https://doi.org/10.23950/jcmk/16189

REFERENCES

  • Abbasov FE, Heybatov IC, Aliyev EH. Myocardial viability assessment in cardiac surgery: clinical practice and prognostic valve. The Cardiologist. 2018; 2(2): 27–38.
  • Nazyrova LA, Baibekov IM, Rakhimova MK. Morphological changes in the myocardium with various types of cardioplegic protection during the correction of congenital heart defects. Anesthesiology, Resuscitation and Perfusology. 2007; 3: 52–54.
  • Bai Y, Mugier, Murakami H. Cilostazol protects the heart against ischemia/reperfusion injury in a rabbit model of myocardial infarction: Focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clin Exp Pharm Phys. 2011; 38: 658–665. https://doi.org/10.1111/j.1440-1681.2011.05550.x
  • Barassi A, Nerlini J, Finazzi. Comparison of the strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. Clin Biochem. 2004; 38: 5040–5050. https://doi.org/10.1016/j.clinbiochem.2005.03.004
  • George V, Moucarbel, Chakib M. Pharmacological therapy for myocardial reperfusion injury. Current Opinion in Pharmacology. 2004; 4: 147–153. https://doi.org/10.1016/j.coph.2003.10.012
  • Buja LM. Modulation of the myocardial response to ischemia. Lab Invest 1998; 78:1345-1373.
  • McDiarmid SV, Busuttil RW, Ascher NL, Burdick J. FK506 (cilostazol) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Transplantation. 1995; 59: 530–536. https://doi.org/10.1097/00007890-199559040-00016
  • Hedström E, Engblom H, Frogner F. Infarct evaluation in man studied in patients with first-time coronary occlusion in comparison to different species – implications for assessment of myocardial salvage. J Cardiovasc Magn Reson. 2009; 11: 38. https://doi.org/10.1186/1532-429X-11-38
  • Heusch G. The coronary circulation as a target of cardioprotection. Cir Res. 2016; 118: 1643–1658. https://doi.org/10.1161/CIRCRESAHA.116.308640
  • Heusch G. Myocardial ischemia/reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020; 17: 773–789. https://doi.org/10.1038/s41569-020-0403-y
  • Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in dogs. J Clin Invest. 1974; 54: 1496–1508. https://doi.org/10.1172/JCI107898
  • McDiarmid SV, Busuttil RW, Ascher NL, Burdick J. FK506 (cilostazol) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Transplantation. 1995; 59: 530–536. https://doi.org/10.1097/00007890-199559040-00016
  • Haushenloy DJ, Chilian W, Crea F. The coronary circulation in acute myocardial ischemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res. 2019; 115: 1143–1155. https://doi.org/10.1093/cvr/cvy286
  • Li J, Xiang X, Gong X. Cilostazol protects mice against myocardial ischemia/reperfusion injury by activating a PPARγ/JAK2/STAT3 pathway. J Biomedicine Pharmotherapy. 2017; 94: 995–1001. https://doi.org/10.1016/j.biopha.2017.07.143
  • Sahin M, Baytaroglu C, Sevgili E. Cardioprotective effect of cilostazol on ischemia-reperfusion injury model. Braz J Cardiovasc Surg. 2022; 37(6): 843–847. https://doi.org/10.21470/1678-9741-2020-0651
  • Inoue M, Sato E, Park AM. Cross-talk between NO and oxidatives, a supersystem that regulates energy metabolism and survival of animals. Free Rad Res. 2000; 33: 757–770. https://doi.org/10.1080/10715760000301281
  • Liu Y, Fong M, Cone J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol. 2000; 36: 351–360. https://doi.org/10.1097/00005344-200009000-00011
  • Manickavasagam S, Ye Y, Lin Y. The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007; 21: 321–330. https://doi.org/10.1007/s10557-007-6036-0
  • Kim SM, Jung JM, Kim BJ. Cilostazol mono and combination treatments in ischemic stroke: an update systematic review and meta-analysis. Stroke 2019; 50(12):3503-3511. https://doi.org/10.1161/STROKEAHA.119.026655
  • Kamel SM, Mahqoub LA, Monira I. Cardioprotective effect of cilostazol versus clopidogrel in experimentally induced myocardial infarction in male albino rats. Az J Pharm Sci. 2015; 51: 2–10. https://doi.org/10.21608/ajps.2015.12494
  • Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: From adenosine receptor to KATP channel. Annu Rev Physiol. 2000; 62: 79–109. https://doi.org/10.1146/annurev.physiol.62.1.79
  • Manickavasagam S, Ye Y, Lin Y. The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007; 21: 321–330. https://doi.org/10.1007/s10557-007-6036-0